Bradenton, Fl. September 14, 2010— HP Ingredients announces that human clinical studies of Citrus Bergamot (Citrus Bergamia Risso) reports an average reduction of 36% in LDL Cholesterol, a 49% decrease in triglycerides, a 22% decrease in blood sugar levels while increasing HDL by up to 40%.
The active ingredients responsible for these benefits are Neoeriocitrin, Naringin, Neoesperidin, Ponceritin, Melitidine and Brutelidine; which are unique to Citrus Bergamot. Clinical trial participants include patients with hypercholesterolemia, patients with both hypercholesterolemia and hypertriglyceridemia.
“4 flavonoids in Citrus Bergamot are linked to 3-metil-3–hydroxy glutarile portion, which is exactly the substrate of HMG-CoA reductase, suggesting that these compounds mimic endogenous HMG-CoA substrate and interfere with the synthesis of mevalonate, a critical compound at the top of the cholesterol synthesis pathway”, Dr. Vincenzo Mollace MD.
Traditional uses of Citrus Bergamot includea digestive tonic and a worming agent and is reputed to be strongly antiseptic with an affinity for the respiratory, digestive and urinary systems, it has also been used for a variety of infections and inflammations of these areas and wound healing.
Citrus Bergamot is available from HP Ingredients in a polyphenolic extract powder and soon a liquid concentrate.
About HP Ingredients: HP Ingredients, a certified Women’s Business Enterprise, was founded in 2001 and now offers more than 200 Standardized Botanical Extracts. HP Ingredients relies on proven research to identify and develop their Proprietary Extracts. HP’s Premier ingredients include Maqui, Bergamonte, LJ100 and Paractin